SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

As reported in Biophotonics Discovery, the team developed a novel microscopy technique that uses a standard fluorescence microscope in combination with imaging software. This method allows scientists ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...

Researchers at the University of Kentucky have developed a cost-effective, non-destructive microscopy technique to study cancer cell metabolism at the single-cell level. Published in Biophotonics ...

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo ...